Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 15/20 | 0.66 |
| ▸ | ABL1 | P00519 | 4/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15095263 | 0.87 | SRC (0.77) | SRCABL1PDGFRB | |
| SCHEMBL4265952 | 0.80 | SRC (1.00) | SRCABL1PDGFRB | |
| SCHEMBL15095298 | 0.73 | SRC (0.54) | SRCABL1PDGFRB | |
| SCHEMBL15095319 | 0.72 | PIK3CG (0.46) | SRCADORA2AADORA1JAK2PIK3CG | |
| SCHEMBL15095302 | 0.71 | SRC (0.58) | SRCABL1PDGFRBADORA2AADORA1 | |
| SCHEMBL5843155 | 0.70 | ALOX15 (0.52) | SRCPDCD1CD274 | |
| SCHEMBL6373767 | 0.69 | CYP2D6 (0.54) | SRCPDCD1CD274ADORA2AADORA1 | |
| SCHEMBL9566466 | 0.68 | HTR2B (0.68) | PDCD1CD274JAK2 | |
| SCHEMBL14009097 | 0.68 | SRC (0.64) | SRCABL1PDGFRBPIK3CG | |
| SCHEMBL15395976 | 0.67 | DHFR (0.42) | SRCADORA1JAK2PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481536-B2 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20110294796-A1 | BENZOTRIAZINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294796-A1 | BENZOTRIAZINE INHIBITORS OF KINASES | SRC, CAMK4, CAMK2G | SRC 1/4885ABL1 15/4885PDGFRB 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.